Review article · 23 Sep 2025
EditorialPublished 26 Sep 2015
Optimal Therapy for Polycythemia Vera and Essential Thrombocythemia: A Different Perspective
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Recent publications have de-emphasized the importance of recombinant interferon alpha (rIFNα) for the treatment of polycythemia vera (PV) or essential thrombocythemia (ET), favoring the use of phlebotomy and/or hydroxyurea. Here we express our reasons for the use of rIFNα early in the course of PV or ET in the absence of a phase 3 trial.
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Blood Research & Hematologic Diseases.
Commentary · 16 Apr 2025
Chronic Bleeding Conditions: Evaluating Risk Factors and Treatment Approaches
Commentary · 17 Mar 2025
Blood Disorders and Their Systemic Effects on Health
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Blood Research & Hematologic Diseases
- SubjectHaematology
- BylineArticles whose byline prints “Richard T Silver”
- BylineArticles whose byline prints “Hans Carl Hasselbalch”
